Balyasny Asset Management LLC Global Blood Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $37.3 Million - $78.5 Million	1,151,518 New	1,151,518 $78.4 Million
Q1 2022 May 16, 2022	SELL	$25.68 - $35.59 $2.67 Million - $3.71 Million	-104,154 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $2.59 Million - $4.19 Million	104,154 New	104,154 $3.05 Million
Q2 2019 Aug 14, 2019	SELL	$52.6 - $63.29 $9.1 Million - $10.9 Million	-172,948 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$39.99 - $53.48 $905,573 - $1.21 Million	-22,645 Reduced 11.58%	172,948 $9.15 Million
Q4 2018 Feb 14, 2019	BUY	$31.54 - $46.67 $5.96 Million - $8.82 Million	188,991 Added 2862.63%	195,593 $8.03 Million
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $1.59 Million - $2.14 Million	-41,972 Reduced 86.41%	6,602 $251,000
Q2 2018 Aug 14, 2018	SELL	$38.7 - $50.15 $1.71 Million - $2.21 Million	-44,146 Reduced 47.61%	48,574 $2.2 Million
Q1 2018 May 15, 2018	BUY	$39.6 - $65.9 $3.67 Million - $6.11 Million	92,720 New	92,720 $4.48 Million
Q4 2017 Feb 14, 2018	SELL	$29.7 - $45.7 $257,706 - $396,538	-8,677 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$25.1 - $31.05 $217,792 - $269,420	8,677	8,677 $269,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.